Skip to main content

Table 2 Clinicopathologic characteristics of the 238 BRAF-mutant NSCLC patients

From: The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients

  Total (n = 238) Class 1 (n = 75) Class 2 (n = 51) Class 3 (n = 32) Non-class 1–3 (n = 80) P-value (1 vs. 2) P-value (1 vs. 3) P-value (2 vs. 3)
Age 0.87 0.70 0.75
 Median (range) 61 (33–86) 61 (42–82) 61 (45–81) 62 (47–81) 59 (33–86)
Gender 0.008 0.017 1
 Male 156 (65.5%) 38 (50.7%) 39 (76.5%) 25 (78.1%) 54 (67.5%)
 Female 80 (33.6%) 35 (46.7%) 12 (23.5%) 7 (21.9%) 26 (32.5%)
 NA 2 (0.8%) 2 (2.7%) 0 (0%) 0 (0%) 0 (0%)
Histology 0.74 0.88 0.81
 Adenocarcinoma 188 (79.0%) 60 (80.0%) 40 (78.4%) 28 (87.5%) 60 (75.0%)
 Squamous cell carcinoma 18 (7.6%) 2 (2.7%) 3 (5.9%) 1 (3.1%) 12 (15.0%)
 Adenosquamous carcinoma 27 (11.3%) 10 (13.3%) 7 (13.7%) 3 (9.4%) 7 (8.8%)
 Large cell carcinoma 5 (2.1%) 3 (4.0%) 1 (2.0%) 0 (0%) 1 (1.2%)
Stage 1 1 1
 Stage IA–IIIA 67 (28.2%) 20 (26.7%) 14 (27.5%) 9 (28.1%) 24 (30.0%)
 Stage IIIB–IVB 164 (68.9%) 54 (72.0%) 35 (68.6%) 21 (65.6%) 54 (67.5%)
 NA 7 (2.9%) 1 (1.3%) 2 (3.9%) 2 (6.3%) 2 (2.5%)
Metastasis 0.43 0.63 1
 M0 171 (71.8%) 55 (73.3%) 34 (66.7%) 22 (68.8%) 60 (75.0%)
 M1 67 (28.2%) 20 (26.7%) 17 (33.3%) 10 (31.2%) 20 (25.0%)
  1. P-values in italics-face denotes statistical significance